The participant will be able to describe the role of rho kinase inhibitors and adenosine agonists as a potential new glaucoma drug class, describe the developments of sustained drug release delivery for glaucoma treatment, and describe challenges in developing gene-based and stem cell-based therapies for glaucoma.
